Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2418363 | 0.98 | CTSK (0.50) | CTSKCTSS | |
| SCHEMBL28618599 | 0.98 | CTSK (0.50) | CTSKCTSS | |
| SCHEMBL6454726 | 0.98 | CTSK (0.50) | CTSKCTSS | |
| SCHEMBL30638293 | 0.98 | CTSK (0.50) | CTSKCTSS | |
| SCHEMBL10706331 | 0.98 | CTSK (0.50) | CTSKCTSS | |
| SCHEMBL28600066 | 0.98 | CTSK (0.50) | CTSKCTSS | |
| SCHEMBL3996361 | 0.95 | CTSK (0.56) | CTSKCTSS | |
| SCHEMBL3252315 | 0.88 | CTSK (0.51) | CTSKCTSS | |
| SCHEMBL15415011 | 0.87 | CA1 (0.42) | CTSKCTSS | |
| SCHEMBL8525452 | 0.85 | ITGB3 (0.42) | CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 936 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113444079-B | Rotaxane molecular machine based on crown ether and preparation method | 浙江工业大学 | 2022-07-01 | — | — | CN | claimed |
| CN-113444079-A | Rotaxane molecular machine based on crown ether and preparation method | 浙江工业大学 | 2021-09-28 | — | — | CN | claimed |
| US-12630632-B2 | Bispecific HER2 and CD3 binding molecules | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4423126-B1 | METHODS OF TREATING CROHN'S DISEASE WITH ANTI-IL23 SPECIFIC ANTIBODY | JANSSEN BIOTECH INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4733320-A2 | METHODS OF TREATING CROHN'S DISEASE WITH ANTI-IL23 SPECIFIC ANTIBODY | Janssen Biotech, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260103510-A1 | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody | JANSSEN BIOTECH INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260083860-A1 | COMPOSITIONS AND METHODS FOR GENOME EDITING | POSEIDA THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4714504-A2 | SAFE AND EFFECTIVE METHOD OF TREATING PSORIASIS WITH ANTI-IL23 SPECIFIC ANTIBODY | Janssen Biotech, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260071005-A1 | BISPECIFIC HER2 AND CD3 BINDING MOLECULES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260062501-A1 | BISPECIFIC HER2 AND CD3 BINDING MOLECULES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260042732-A1 | Sulfur-containing Compounds and Compositions Thereof for Delivery of Nucleic Acids | POSEIDA THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| WO-2002012502-A2 | ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES | CENTOCOR, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012500-A2 | ANTI-IL-12 ANTIBODIES, COMPOSITIONS, METHODS AND USES | CENTOCOR, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012501-A2 | ANTI-DUAL INTEGRIN ANTIBODIES, COMPOSITIONS, METHODS AND USES | CENTOCOR, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| EP-0923570-A1 | PYRIDYL ALKENE- AND PYRIDYL ALKINE- ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | Klinge Pharma GmbH (DE) | 1999-06-23 | — | — | EP | disclosed |
| WO-1997048696-A1 | PYRIDYL ALKENE- AND PYRIDYL ALKINE- ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | KLINGE PHARMA GMBH (DE) | 1997-12-24 | — | — | WO | disclosed |
| EP-0538384-A4 | OXAMIDES | SMITHKLINE BEECHAM CORP (US) | 1995-04-12 | — | — | EP | disclosed |
| US-5393788-A | Phenylalkyl oxamides | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0538384-A1 | OXAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-28 | — | — | EP | disclosed |
| WO-1992000968-A1 | OXAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1992-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062501-A1 | BISPECIFIC HER2 AND CD3 BINDING MOLECULES | ERBB2, CD2, TNFRSF9 | CTSK 1297/4885CTSS 701/4885 |
| US-20260042732-A1 | Sulfur-containing Compounds and Compositions Thereof for Delivery of Nucleic Acids | ELAVL1, NSUN3, SLC10A1 | CTSK 4121/4885CTSS 1699/4885 |
| US-20260071005-A1 | BISPECIFIC HER2 AND CD3 BINDING MOLECULES | CD2, ERBB2, CD4 | CTSK 2181/4885CTSS 1682/4885 |
| US-12630632-B2 | Bispecific HER2 and CD3 binding molecules | CD274, PDCD1LG2, CD2 | CTSK 1472/4885CTSS 1092/4885 |
| US-20260103510-A1 | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody | IL23R, IL17A, IL15 | CTSK 334/4885CTSS 2047/4885 |
| US-20260083860-A1 | COMPOSITIONS AND METHODS FOR GENOME EDITING | TRMT1L, SPPL2B, DNMT3A | CTSK 4151/4885CTSS 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.